ENV Stock Recent News
ENV LATEST HEADLINES
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the U.S. Department of Defense (“DoD”) is providing $876,000 to advance a strategy to ident.
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the “Company'”), announces the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial, titled, “Phase II study of Apalutamide with Carotuximab (ENV105) in Metastatic, Castration Resistant Prostate Cancer,” began with the safety lead-in, which combined apalutamide, a standard of care.
BERWYN, Pa. , March 3, 2025 /PRNewswire/ -- Key Wealth, the wealth management business of KeyBank and Envestnet, a leading provider of integrated technology, intelligent data, and wealth solutions, announced today that they have expanded their multi-year relationship.
STAMFORD, Conn.--(BUSINESS WIRE)--NewEdge Wealth, LLC, a registered investment advisor specializing in serving ultra high net worth families, family offices and institutional clients, announced today that financial advisors can now access the innovative Structured Note Strategies from its investment platform, NewEdge Investment Solutions (NEIS), through the Envestnet and SMArtX platforms. This expansion builds upon NewEdge's existing relationship with Halo Investing, a platform focused on prote.
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205, a groundbreaking new drug to treat chemotherapy drug resistance and cachexia. This funding will accelerate the Company's research efforts to develop ENV205,.
BERWYN, Pa.--(BUSINESS WIRE)--Envestnet (NYSE: ENV), a leading provider of integrated technology, data intelligence and wealth solutions, today announced that the Company will release its third quarter 2024 financial results on Thursday, November 7, 2024 after market close. Due to the pending transaction with Bain Capital, the Company will not be providing guidance for the fourth quarter and will not host a conference call or webcast to review the third quarter 2024 financial results. About Env.
Kasowitz Benson Torres Is Acting As Lead Counsel For FinancialApps NEW YORK , Sept. 27, 2024 /PRNewswire/ -- Financial technology pioneer FinancialApps's $100 million lawsuit for trade secret misappropriation, tortious interference, and unfair competition against wealth management company Envestnet ($ENV) – whose acquisition by Bain Capital in a $4.5 billion deal was approved by shareholders earlier this week – is now headed to a jury trial in Delaware Federal Court.
BERWYN, Pa. , Sept. 23, 2024 /PRNewswire/ -- Envestnet (NYSE: ENV), a leading provider of integrated technology, data intelligence, and wealth solutions, has been recognized as an industry leader at the 2024 WealthManagement.com Industry Awards (the "Wealthies").
SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP , a leading stockholder rights law firm, announced today that it has initiated an investigation into the board members of Envestnet, Inc. (NYSE: ENV) concerning potential breaches of fiduciary duties related to the proposed sale of the Company to private equity firm Bain Capital.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Envestnet, Inc. (NYSE: ENV) to Bain Capital for $63.15 in cash per share is fair to Envestnet shareholders. Halper Sadeh encourages Envestnet shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Envestnet and its bo.